Physician profile
Timothy S Collins
NPI 1023064896
$18,994.82
in general payments reported to CMS, 2019-2025
13 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4.36 · 2020: $5,790 · 2021: $2,221 · 2022: $1,624 · 2023: $5,012 · 2024: $4,130 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,170 · Food and Beverage: $757 · Education: $227 · Travel and Lodging: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,170.00 |
| Food and Beverage | $756.52 |
| Education | $226.75 |
| Travel and Lodging | $202.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $8,582.07 | 2019-2024 | |
| Emd Serono, INC. | $3,000.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $2,070.34 | 2021-2025 | Akeega, Erleada, Balversa |
| Bayer Healthcare Pharmaceuticals INC. | $1,844.00 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $1,708.25 | 2021-2025 | Enhertu |
| Eisai INC. | $1,057.42 | 2024-2025 | |
| Astellas Pharma US INC | $282.35 | 2023-2025 | Xtandi, Padcev |
| Genzyme Corporation | $137.57 | 2021-2023 | |
| Aveo Pharmaceuticals, INC. | $113.15 | 2024-2025 | |
| Janssen Biotech, INC. | $99.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $46.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $26.71 | 2025 | |
| Glaxosmithkline, LLC. | $26.39 | 2025 | Ojjaara, Blenrep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.